Pharmaceutical

AbbVie makes psychedelic play with $2bn Gilgamesh collaboration

The two companies will develop neuroplastogens for psychiatric disorders as psychedelic market activity ramps up.

May 15, 2024 - 04:00
AbbVie makes psychedelic play with $2bn Gilgamesh collaboration
The two companies will develop neuroplastogens for psychiatric disorders as psychedelic market activity ramps up.
Read the original article

Tags:

Previous Article

Walden Biosciences teams up with Primula for kidney disease study 

Next Article

Cytokinetics looks to take on BMS’ Camzyos in hypertrophic cardiomyopathy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence

Biogen completes $1.15bn HI-Bio acquisition to expand i...

Jul 4, 2024

Opinion: OTC naloxone is a baby step toward making the life-saving medication accessible

Opinion: OTC naloxone is a baby step toward making the ...

Apr 17, 2023

EC approves Daiichi Sankyo’s Vanflyta for acute myeloid leukaemia

EC approves Daiichi Sankyo’s Vanflyta for acute myeloid...

Nov 12, 2023